Back
Repare Therapeutics
IPORPTX.NASDAQPast

Repare Therapeutics

Developer of oncology drugs

Foundation year: 2016
Profitability
+62.45%
IPO date
18/06/2020

About

Total Funding 

$251.7M


Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.